Abstract 272P
Background
High rate of clinical fractures was reported during adjuvant HT trials (9-14% in BIG 1-98, ATAC, IES). Since 2015, in Italy, bisphosphonates and denosumab are reimbursed for prevention of bone fractures in EBC HR+ postmenopausal pts receiving HT, regardless of T-score values (Note 79 of AIFA-Agenzia Italiana del Farmaco). In 2019, these drugs were administered only in 25% of potentially beneficiary pts. The P&P is a nationwide Bone Health (BH) management project designed to improve adherence to recommendations regarding fracture risk assessment and risk prevention measures in pts receiving HT for HR+ EBC.
Methods
The BH management model P&P was developed in 10 Italian cancer centres and includes: 1- training of multidisciplinary team and presentation of a BH management model by the oncologist (with referral to the Bone Specialist if osteoporosis); 2- implementation of this model in every centre; 3- evaluation, after 12 months, of rate of EBC HR+ pts in postmenopausal status (natural, surgical, secondary to chemotherapy or hormonal blockage) assessed for BH within 30 days from the start of adjuvant HT; 4- evaluation, after 12 months, of rate of EBC HR+ pts receiving therapy within 90 days from the start of adjuvant HT, according to the criteria for reimbursement by AIFA.
Results
At 12 months after implementation of P&P, data are available from 6 centres (IRCCS Negrar, Ancona Hospital, IRCCS San Martino Genova, Poliambulanza Brescia, Cardarelli Napoli, Papa Giovanni XXIII Bergamo) in 1,551 postmenopausal EBC HR+ pts. The first analysis reports that 83% of EBC HR+ patients who started adjuvant HT were assessed for BH within 30 days compared to 43% in the 2019 national survey and 68% of pts started bisphosphonates/denosumab compared to 25% in the 2019 national survey.
Conclusions
Implementation of the P&P model has been shown to increase the rate of postmenopausal EBC HR+ pts on adjuvant HT assessed for BH and treated with bisphosphonate/denosumab to reduce the risk of bone fractures. A new project is ongoing to assess the rate of fractures in Italian pts after the approval of Note 79 by AIFA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Gori.
Funding
Amgen.
Disclosure
C. Bighin: Financial Interests, Personal, Research Grant: Novartis, Roche, Lilly, Eisai, Gilead, Italfarmaco. F. Puglisi: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Daiichi Sankyo, Celgene, Eisai, Eli Lilly, Exact Sciences, Gilead, Ipsen, Menarini, MSD, Novartis, Pierre Fabre, Roche, Pfizer, Seagen, Takeda, Viatris; Financial Interests, Personal, Research Grant: AstraZeneca, Eisai, Roche. A. Fabi: Financial Interests, Personal, Advisory Board: Roche, Pfizer, Novartis, Lilly, Seagen, Gilead, Exact Science, Dompè Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
273P - A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2
Presenter: Patrick Neven
Session: Poster session 02
274P - Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study
Presenter: Joyce O'Shaughnessy
Session: Poster session 02
275P - Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
Presenter: Francesco Schettini
Session: Poster session 02
276P - Development and external validation of an artificial intelligence (AI)-based machine learning model (ML) for predicting pathological complete response (pCR) in hormone-receptor (HoR)-positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT)
Presenter: Luca Mastrantoni
Session: Poster session 02
277P - Fat body mass independently predicts incident vertebral fractures in breast cancer patients given adjuvant aromatase inhibitor therapy and denosumab
Presenter: Greta Schivardi
Session: Poster session 02
278P - Association between tamoxifen and endoxifen plasma levels and clotting proteins in patients with primary breast cancer
Presenter: Daan van Dorst
Session: Poster session 02
279P - Early changes in bone turnover biomarkers during AI therapy are related to loss bone mineral density, data of the B-ABLE cohort
Presenter: Tamara Martos Cardenas
Session: Poster session 02
280P - Adjuvant aromatase inhibitors in patients with PIK3CA mutation early breast cancer
Presenter: Kristin Reinhardt
Session: Poster session 02
282P - Analysis of Prosigna in hormone receptor-positive early-stage breast cancer cohort after 8 years of experience at a single institution
Presenter: DANIEL MORCHÓN ARAUJO
Session: Poster session 02